Preclinical data is encouraging but does not change the company's near-term risk profile. The key catalyst to watch is the start of the multiple ascending dose study in Q4 2026.
Price Chart
Executive Summary
Artelo Biosciences announced new preclinical data for ART26.12, its FABP5 inhibitor, showing efficacy comparable to naproxen in an osteoarthritis pain model with significantly less gastric tissue damage. The data expands the potential utility of ART26.12 beyond neuropathic pain into the large OA market, but remains preclinical — no new clinical data or regulatory milestones were achieved. The company also noted preparations for a multiple ascending dose study with enrollment expected in Q4 2026.
Key Facts
- ART26.12 demonstrated efficacy comparable to naproxen in a nonclinical OA pain model over 4 weeks.
- ART26.12 showed significantly less stomach tissue damage (non-glandular hyperkeratosis) vs. naproxen.
- Data presented at the International Cannabinoid Research Society 2026 Annual Symposium in Dijon, France.
- Artelo anticipates enrollment for a multiple ascending dose study in healthy volunteers to commence in Q4 2026.
- ART26.12 is Artelo's lead FABP5 inhibitor, initially under development for chemotherapy-induced peripheral neuropathy (CIPN).
Financial Impact
No financial figures disclosed; preclinical data only, no revenue impact.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- Company has a $4M market cap with limited cash runway — dilution risk is high.
- No regulatory milestones or approvals imminent; timeline to commercialization is years away.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3328460 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $3.11 | awaiting T+60 | — | $2.20 (+29.26%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.20 (−41.33%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.20 (−67.79%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.20 (+92.98%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.20 (+109.52%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.20 (−98.20%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.20 (−50.68%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.20 (+61.76%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.20 (+50.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers